What happened Neuronetics (NASDAQ: STIM), a company that focuses on what it describes as "products that improve the quality of life for patients who suffer from psychiatric disorders," shot 39% higher on Tuesday. Investors were likely impressed by the company's potential as indicated in its first-quarter results. So what Neuronetics earned $12.3 million in revenue for the quarter, 7% higher on a year-over-year basis. As is its habit of late, the healthcare company posted a net loss. However, this narrowed to just under $7.9 million ($0.31 per share) from the Q1 2020 shortfall of $12.6 million. Image source: Getty Images. Both headline figures beat the average analyst estimates of $11.6 million for revenue and a bottom-line deficit of $0.33 per share. Neuronetics specializes in transcranial magnetic stimulation (TMS) in which magnetic fields are used to stimulate nerve cells located in a part of the brain associated with mood in order to help alleviate clinical depression. With depression apparently on the rise due to the psychological effects of the coronavirus pandemic, Neuronetics is experiencing significantly higher demand for its TMS therapy. The company reported that it has witnessed a 30% rise in patients requesting appointments. Now what Neuronetics has increased its guidance for full-year 2021: Revenue should be $59 million to $63 million, up from the previous $58 million to $62 million estimate. A profitability estimate wasn't provided. Regardless, investors like the sound of a 30% demand rise; it's no wonder that the stock rose at a rate not far from that figure. 10 stocks we like better than Neuronetics, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Neuronetics, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.Source